Product Description
Delafloxacin (formerly WQ-3034, ABT492, RX-3341) is a novel fluoroquinolone chemically distinct from currently marketed fluoroquinolones with the absence of a protonatable substituent conferring a weakly acidic character to the molecule. This property results in increased intracellular penetration and enhanced bactericidal activity under acidic conditions that characterize the infectious milieu at a number of sites. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986682/)
Mechanisms of Action: DNA Gyrase Inhibitor,TOP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Belgium | Brazil | Chile | Croatia | Czech | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Jordan | Latvia | Lebanon | Lithuania | Netherlands | Peru | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Healthy Volunteers|Pneumonia, Bacterial
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20213149 | P1 |
Completed |
Pneumonia, Bacterial |
2022-06-24 |
|
| CTR20213308 | P1 |
Not yet recruiting |
Healthy Volunteers |
None |